Cryptococcal meningitis

T Bicanic, TS Harrison - British medical bulletin, 2004 - academic.oup.com
Cryptococcal meningitis is a common opportunistic infection in AIDS patients, particularly in
Southeast Asia and Africa. Cases also occur in patients with other forms of …

Combination treatment of invasive fungal infections

PK Mukherjee, DJ Sheehan, CA Hitchcock… - Clinical microbiology …, 2005 - Am Soc Microbiol
The persistence of high morbidity and mortality from systemic fungal infections despite the
availability of novel antifungals points to the need for effective treatment strategies …

An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients

AH Limper, KS Knox, GA Sarosi, NM Ampel… - American journal of …, 2011 - atsjournals.org
With increasing numbers of immune-compromised patients with malignancy, hematologic
disease, and HIV, as well as those receiving immunosupressive drug regimens for the …

NLLSS: predicting synergistic drug combinations based on semi-supervised learning

X Chen, B Ren, M Chen, Q Wang… - PLoS computational …, 2016 - journals.plos.org
Fungal infection has become one of the leading causes of hospital-acquired infections with
high mortality rates. Furthermore, drug resistance is common for fungus-causing diseases …

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

AE Brouwer, A Rajanuwong, W Chierakul, GE Griffin… - The Lancet, 2004 - thelancet.com
Background It frequently takes more than 2 weeks for drug treatments for cryptococcal
meningitis to sterilise cerebrospinal fluid (CSF). In-vitro and animal studies lend support to …

Combination drugs, an emerging option for antibacterial therapy

G Cottarel, J Wierzbowski - Trends in biotechnology, 2007 - cell.com
The emerging and sustained resistance to antibiotics and the poor pipeline of new
antibacterials is creating a major health issue worldwide. Bacterial pathogens are …

[HTML][HTML] Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

P Van Dijck, J Sjollema, BPA Cammue, K Lagrou… - Microbial Cell, 2018 - ncbi.nlm.nih.gov
Unlike superficial fungal infections of the skin and nails, which are the most common fungal
diseases in humans, invasive fungal infections carry high morbidity and mortality …

Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for …

A Loyse, D Wilson, G Meintjes, JN Jarvis… - Clinical infectious …, 2012 - academic.oup.com
Abstract (See the Editorial Commentary by Bennett, on pages 129–30.) Background. HIV-
associated cryptococcal meningitis is associated with an estimated 600 000 deaths …

Towards a mechanism-based analysis of pharmacodynamic drug–drug interactions in vivo

DM Jonker, SAG Visser, PH Van Der Graaf… - Pharmacology & …, 2005 - Elsevier
The combination of drugs is a common practice for enhancing the efficiency of drug
treatment, but selection of the optimal combination and the optimal doses remains a matter …

[PDF][PDF] Neurological complications in kidney transplant recipients

C Ponticelli, MR Campise - Journal of nephrology, 2005 - researchgate.net
Neurological complications are frequent in renal transplant recipients and may largely
contribute to morbidity and mortality. The postransplant neurological complications may be …